Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, GLP-1RA, Other

JPMorgan Raises $500M Venture Fund for New Obesity Therapies

Here is a brief preview of this blast: JP Morgan reported its asset-management arm raised a $500M+ venture fund to invest in new weight-loss therapies (view article). According to the article, the fund (270 Life Sciences Private Capital Fund I) closed earlier this month and will have a focused approach on obesity. For context, in November 2023, JP Morgan analysts projected the global GLP-1RA market to reach over $100B by 2030, with GLP-1RA users in the US reaching 30M by the end of the decade (view report). Additionally, JP Morgan stated it has already made five investments, including a $100M Series A round for Enlaza Therapeutics in April 2024. Below, FENIX provides brief insight into JP Morgan’s venture fund.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.